Advertisement
Journal Home
Search for

Volume 90, Issue 2, Pages 135-142 (March 2010)


View previous. 7 of 10 View next.

Experimental tuberculosis: Designing a better model to test vaccines against tuberculosis

Denise Morais Fonsecaaemail address, Rogério Silva Rosadaaemail address, Marina Oliveira e Paulaaemail address, Pryscilla Fanini Wowkaemail address, Luis Henrique Francoaemail address, Edson Garcia Soaresbemail address, Célio Lopes Silvaaemail address, Vânia Luiza Deperon BonatoaCorresponding Author Informationemail address

Received 20 October 2009; received in revised form 20 January 2010; accepted 26 January 2010. published online 26 February 2010.

Summary 

Experimental models of infection are good tools for establishing immunological parameters that have an effect on the host–pathogen relationship and also for designing new vaccines and immune therapies. In this work, we evaluated the evolution of experimental tuberculosis in mice infected with increasing bacterial doses or via distinct routes. We showed that mice infected with low bacterial doses by the intratracheal route were able to develop a progressive infection that was proportional to the inoculum size. In the initial phase of disease, mice developed a specific Th1-driven immune response independent of inoculum concentration. However, in the late phase, mice infected with higher concentrations exhibited a mixed Th1/Th2 response, while mice infected with lower concentrations sustained the Th1 pattern. Significant IL-10 concentrations and a more preeminent T regulatory cell recruitment were also detected at 70 days post-infection with high bacterial doses. These results suggest that mice infected with higher concentrations of bacilli developed an immune response similar to the pattern described for human tuberculosis wherein patients with progressive tuberculosis exhibit a down modulation of IFN-γ production accompanied by increased levels of IL-4. Thus, these data indicate that the experimental model is important in evaluating the protective efficacy of new vaccines and therapies against tuberculosis.

a Núcleo de Pesquisas em Tuberculose, Departamento de Bioquímica e Imunologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Av. Bandeirantes, 3900, CEP 14049-900 Ribeirão Preto, SP, Brazil

b Departamento de Patologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil

Corresponding Author InformationCorresponding author. Tel.: +55 16 36023089; fax: +55 16 3602 4595.

 This work was done at “Núcleo de Pesquisas em Tuberculose, Departamento de Bioquímica e Imunologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil”.

PII: S1472-9792(10)00017-X

doi:10.1016/j.tube.2010.01.005


View previous. 7 of 10 View next.

Advertisement